This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in HEXO Corp. (NYSE:HEXO) and Lipocine Inc. (NASDAQ:LPCN). The two are both Drugs Generic companies that compete with one another.
Valuation and Earnings
Demonstrates HEXO Corp. and Lipocine Inc. earnings per share (EPS), top-line revenue and valuation.
Profitability
Table 2 shows us HEXO Corp. and Lipocine Inc.s return on equity, return on assets and net margins.
Analyst Ratings
The Ratings and Recommendations for HEXO Corp. and Lipocine Inc. are featured in the next table.
HEXO Corp.s average price target is $4, while its potential upside is 82.65%.
Insider & Institutional Ownership
Roughly 9.15% of HEXO Corp. shares are owned by institutional investors while 13.4% of Lipocine Inc. are owned by institutional investors. Insiders owned 8.04% of HEXO Corp. shares. Insiders Competitively, owned 3.4% of Lipocine Inc. shares.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year HEXO Corp. has weaker performance than Lipocine Inc.
Summary
HEXO Corp. beats on 8 of the 10 factors Lipocine Inc.
Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of mens and womens health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The companys pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Read the rest here:
Contrasting of HEXO Corp. (HEXO) and Lipocine Inc. (NASDAQ:LPCN) - MS Wkly
